|
ACS Nano
|
1 |
0.08 |
|
|
|
Acta Biomaterialia
|
3 |
0.99 |
|
|
|
Advanced Functional Materials
|
1 |
0.29 |
|
|
|
Advanced Materials
|
3 |
2.10 |
|
|
|
American Journal of Clinical Nutrition
|
1 |
0.06 |
|
|
|
American Journal of Human Genetics
|
2 |
0.74 |
|
|
|
American Journal of Obstetrics and Gynecology
|
1 |
0.10 |
|
|
|
American Journal of Pathology
|
1 |
0.14 |
|
|
|
American Journal of Respiratory and Critical Care Medicine
|
5 |
0.37 |
|
|
|
Analytical Chemistry
|
7 |
5.60 |
|
|
|
Anesthesiology
|
8 |
4.83 |
|
|
|
Angewandte Chemie International Edition
|
5 |
3.58 |
|
|
|
Annals of Emergency Medicine
|
1 |
0.11 |
|
|
|
Annals of Internal Medicine
|
3 |
0.79 |
|
|
|
Annals of Neurology
|
5 |
1.19 |
|
|
|
Annals of Surgery
|
3 |
1.18 |
|
|
|
Annals of the Rheumatic Diseases
|
25 |
11.43 |
|
Myeloid dendritic cell subsets characterise muscle in patients with inclusion body myositis and correlate with the IFN-γ pathway and effector T cell markers
|
0.37 |
|
Response of ultrasound-assessed synovitis to baricitinib, in monotherapy and combined with methotrexate, compared with etanercept in rheumatoid arthritis: a randomised, international, multicentre trial
|
0.06 |
|
Frequency and characteristics of axial involvement in psoriatic arthritis: results from the International Multicentre AXIS Study
|
0.18 |
|
Human blood vessel organoids recapitulate key mechanisms of transition from vasculopathy to fibrosis in systemic sclerosis
|
0.95 |
|
Neutrophil transcriptomics in SLE reveals intrinsic disease signatures, shared ex vivo adaptation, and transcriptional reset after CAR T-cell therapy
|
0.11 |
|
Inhibition of the type I interferon receptor pathway protects against muscle weakness induced by dermatomyositis serum
|
0.03 |
|
Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST score
|
0.10 |
|
An app-based nonpharmacological intervention improves patient-reported disease activity, functionality, and quality of life in patients with axial spondyloarthritis: a randomised controlled trial
|
1.00 |
|
Progression from at-risk state to clinical and severe systemic lupus erythematosus involves molecular dysregulations potentially reversible by biologics: implications for early diagnosis and treatment
|
0.04 |
|
The epigenomic landscape of primary tissues in osteoarthritis
|
0.67 |
|
A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis
|
0.14 |
|
The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)
|
0.14 |
|
Identification of novel fibroblast subsets in diffuse cutaneous systemic sclerosis
|
1.00 |
|
Inflammation rather than anticitrullinated protein antibodies is associated with cardiovascular mortality in RA: insights from rheumatoid arthritis and coronary artery disease cohorts
|
0.22 |
|
A de novo dominant-negative PSMB8 mutation causes severe CANDLE/PRAAS due to arrested proteasome biogenesis
|
0.26 |
|
Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts
|
0.42 |
|
Entheseal tissue signature in response to IL-17A inhibition in psoriatic arthritis: results from the EBIO entheseal biopsy study
|
0.88 |
|
SLE classification criteria item relationships: implications on SLE as a disease entity
|
0.60 |
|
Collagen-binding integrin α11β1 contributes to joint destruction in arthritic hTNFtg mice
|
0.89 |
|
A glossary of signs and symptoms of giant cell arteritis
|
0.10 |
|
AYLo study–elevated relapse risk and dysregulated proinflammatory signalling in giant cell arteritis patients with mosaic loss of the Y chromosome
|
1.00 |
|
Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study
|
0.06 |
|
Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register
|
1.00 |
|
Influence of canstatin on fibroblast-driven hypervascularisation in rheumatoid arthritis
|
1.00 |
|
Exploring the limit of image resolution for human expert classification of vascular ultrasound images in giant cell arteritis and healthy subjects: the GCA-US-AI project
|
0.21 |
|
|
Arthritis & Rheumatology
|
13 |
6.02 |
|
High‐resolution deep learning DIXON MRI of the sacroiliac joints is non‐inferior to standard MRI in patients with suspected axial Spondyloarthritis
|
0.92 |
|
18F‐Fluorodeoxyglucose Positron Emission Tomography Imaging Assessment within a Randomized Controlled Trial in Giant Cell Arteritis
|
0.17 |
|
Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis With Polyangiitis: Findings From a Large European Cohort
|
0.21 |
|
Decision tree analysis as a preliminary evidence‐based tool for identifying the syndrome of undifferentiated recurrent fever in children compared with hereditary recurrent fevers and periodic fever, aphthosis, pharyngitis and adenitis syndrome
|
0.11 |
|
The impact of non‐steroidal anti‐inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: 10‐year results from an inception cohort
|
0.94 |
|
Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation
|
1.00 |
|
Transition from psoriasis to psoriatic arthritis is characterized by distinct alterations in peripheral blood Tc17, Th17 and CD4+ TEM cells
|
1.00 |
|
Efficacy and Safety of ABBV-154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo-Controlled Trial
|
0.07 |
|
Recognition of Glycine Versus Nonglycine Citrulline Motifs Dictating the scpHLA/scp Class scpII/scp Association of Anticitrullinated Protein Antibodies: Insights From Autoantibody Profiling of 6,900 Scandinavian Patients With Rheumatoid Arthritis
|
0.12 |
|
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With scpJAK/scp Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries
|
0.07 |
|
Clinical Impact of Multiparametric Contrast‐Enhanced Dual‐Energy Computed Tomography in Arthritis Imaging: A Prospective Single‐Center Study
|
0.75 |
|
Antifibrotic effects of specific targeting of the 5-hydroxytryptamine 2B receptor (5-HT2BR) in murine models and ex vivo models of scleroderma skin
|
0.62 |
|
A randomized, double‐blind, placebo‐controlled trial of abatacept for the treatment of relapsing, non‐severe, granulomatosis with polyangiitis
|
0.03 |
|
|
Brain
|
7 |
2.55 |
|
|
|
British Journal of Surgery
|
5 |
1.50 |
|
|
|
Cancer Cell
|
2 |
0.99 |
|
|
|
Cell
|
5 |
2.28 |
|
|
|
Cell Host & Microbe
|
4 |
0.83 |
|
|
|
Cell Metabolism
|
4 |
1.08 |
|
|
|
Cell Stem Cell
|
1 |
0.05 |
|
|
|
Chemical Science
|
1 |
0.22 |
|
|
|
Chest
|
1 |
0.87 |
|
|
|
Circulation
|
2 |
0.10 |
|
|
|
Clinical Infectious Diseases
|
6 |
0.54 |
|
|
|
Critical Care Medicine
|
8 |
3.53 |
|
|
|
Current Biology
|
3 |
0.67 |
|
|
|
Developmental Cell
|
2 |
0.13 |
|
|
|
Diabetes Care
|
7 |
0.97 |
|
|
|
Environmental Health Perspectives
|
2 |
0.06 |
|
|
|
Environmental Pollution
|
1 |
0.22 |
|
|
|
Environmental Research
|
6 |
2.19 |
|
|
|
Environmental Science and Technology
|
4 |
2.70 |
|
|
|
European Heart Journal
|
3 |
1.49 |
|
|
|
Gastroenterology
|
2 |
0.25 |
|
|
|
Gut
|
13 |
3.45 |
|
|
|
Hepatology
|
5 |
0.83 |
|
|
|
IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS)
|
2 |
1.86 |
|
|
|
Immunity
|
5 |
1.19 |
|
|
|
International Journal of Epidemiology
|
1 |
0.21 |
|
|
|
International Journal of Obesity
|
5 |
2.38 |
|
|
|
JAMA Internal Medicine
|
2 |
0.20 |
|
|
|
JAMA Psychiatry
|
10 |
4.07 |
|
|
|
JAMA Surgery
|
4 |
1.77 |
|
|
|
JAMA: The Journal of the American Medical Association
|
6 |
0.70 |
|
|
|
Journal of Biological Chemistry
|
4 |
1.30 |
|
|
|
Journal of Bone and Joint Surgery-American Volume
|
2 |
0.20 |
|
|
|
Journal of Clinical Endocrinology & Metabolism
|
8 |
2.98 |
|
|
|
Journal of Clinical Investigation
|
8 |
2.77 |
|
|
|
Journal of Clinical Oncology
|
1 |
0.06 |
|
|
|
Journal of Experimental Medicine
|
5 |
0.44 |
|
|
|
Journal of Hepatology
|
11 |
2.68 |
|
|
|
Journal of Infectious Diseases
|
14 |
6.26 |
|
|
|
Journal of Neuroscience
|
10 |
6.31 |
|
|
|
Journal of Physiology
|
3 |
2.29 |
|
|
|
Journal of Thoracic and Cardiovascular Surgery
|
1 |
0.15 |
|
|
|
Journal of the American Academy of Child and Adolescent Psychiatry
|
1 |
0.02 |
|
|
|
Journal of the American Academy of Dermatology
|
6 |
1.18 |
|
|
|
Journal of the American Chemical Society
|
3 |
2.96 |
|
|
|
Journal of the American College of Cardiology
|
2 |
0.26 |
|
|
|
Journal of the American Society of Nephrology
|
4 |
0.55 |
|
|
|
Journal of the National Cancer Institute
|
3 |
0.39 |
|
|
|
Kidney International
|
16 |
6.58 |
|
|
|
Molecular Cell
|
1 |
0.10 |
|
|
|
Molecular Psychiatry
|
27 |
9.40 |
|
|
|
Nature
|
12 |
4.22 |
|
|
|
Nature Cell Biology
|
1 |
0.83 |
|
|
|
Nature Communications
|
103 |
47.20 |
|
|
|
Nature Genetics
|
3 |
0.31 |
|
|
|
Nature Human Behaviour
|
2 |
0.41 |
|
|
|
Nature Immunology
|
8 |
3.32 |
|
|
|
Nature Medicine
|
16 |
3.45 |
|
|
|
Nature Methods
|
1 |
0.18 |
|
|
|
Nature Neuroscience
|
4 |
0.76 |
|
|
|
Nature Structural & Molecular Biology
|
2 |
1.13 |
|
|
|
Neuron
|
3 |
0.94 |
|
|
|
PLOS Biology
|
10 |
3.96 |
|
|
|
PLOS Medicine
|
5 |
0.56 |
|
|
|
Plant Biotechnology Journal
|
1 |
0.92 |
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
|
21 |
8.87 |
|
|
|
Proceedings of the Royal Society B
|
2 |
1.18 |
|
|
|
Radiology
|
9 |
4.08 |
|
|
|
Science
|
6 |
2.06 |
|
|
|
Science Advances
|
18 |
8.31 |
|
|
|
Science Translational Medicine
|
5 |
3.79 |
|
|
|
The BMJ
|
3 |
0.13 |
|
|
|
The EMBO Journal
|
5 |
4.01 |
|
|
|
The ISME Journal: Multidisciplinary Journal of Microbial Ecology
|
4 |
2.81 |
|
|
|
The Journal of Allergy and Clinical Immunology
|
11 |
2.82 |
|
|
|
The Journal of Physical Chemistry Letters
|
1 |
0.08 |
|
|
|
The Lancet
|
8 |
2.05 |
|
Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial
|
0.36 |
|
Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study
|
0.06 |
|
Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases
|
0.63 |
|
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
|
0.24 |
|
Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: a pooled, prospective cohort study
|
0.03 |
|
A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trial
|
0.43 |
|
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
|
0.20 |
|
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial
|
0.11 |
|
|
The Lancet Diabetes & Endocrinology
|
3 |
0.68 |
|
|
|
The Lancet Global Health
|
5 |
0.63 |
|
|
|
The Lancet Psychiatry
|
6 |
0.69 |
|
|
|
The New England Journal of Medicine
|
11 |
1.33 |
|
|
|
Water Research
|
1 |
1.00 |
|
|